-
Product Insights
Fibromyalgia (Fibromyalgia Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Fibromyalgia (Fibromyalgia Syndrome) - Drugs In Development, 2023’, provides an overview of the Fibromyalgia (Fibromyalgia Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fibromyalgia (Fibromyalgia Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Sector Analysis
Chronic Low Back Pain (CLBP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
CLBP Marketed and Pipeline Drugs Report Overview Chronic low back pain (CLBP) is defined as pain that continues for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain (BP) has been treated. It represents the second-leading cause of disability worldwide and is a major health and economic problem. CLBP is a complex disease with high heterogeneity and is increasingly dubbed a mixed pain syndrome with neuropathic and injurious components. CLBP develops in...